Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 18/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.42 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
| ▸ | ATF4 | P18848 | 1/20 | 0.41 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22627866 | 0.94 | ATF4 (0.40) | SCN9AGCGRATF4 | |
| SCHEMBL22627572 | 0.89 | TRPV1 (0.43) | GCGRATF4 | |
| SCHEMBL25814579 | 0.89 | ATF4 (0.43) | GCGRATF4 | |
| SCHEMBL25809433 | 0.89 | ATF4 (0.47) | GCGRATF4 | |
| SCHEMBL22956150 | 0.89 | ATF4 (0.41) | SCN9ASCN10AATF4 | |
| SCHEMBL22628192 | 0.87 | ALDH1A1 (0.43) | GCGRATF4 | |
| SCHEMBL22627579 | 0.87 | ATF4 (0.42) | GCGRATF4 | |
| SCHEMBL22956162 | 0.86 | SCN9A (0.42) | SCN9ASCN10AGCGRATF4 | |
| SCHEMBL22628207 | 0.86 | ATF4 (0.41) | GCGRATF4 | |
| SCHEMBL22628189 | 0.85 | ATF4 (0.41) | GCGRATF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913727-B2 | Modulators of the integrated stress pathway | ABBVIE INC. (US) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913727-B2 | Modulators of the integrated stress pathway | ATF4, ATF1, DDIT3 | SCN9A 4487/4885SCN10A 4332/4885GCGR 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.